NCT04533347Phase 2Completed

Tafenoquine in Patients With Mild to Moderate COVID-19

Study sponsor: 60 Degrees Pharmaceuticals LLC

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-06-30Actual

Enrollment · participants86Actual

Source updated2025-01-07Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

COVID 19 Disease

Treatments or interventions studied

Tafenoquine Oral TabletDrugAlso known as ARAKODA™, KODATEF™
PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Number of Patients With Clinical Recovery of COVID-19 Symptoms on Day 14; description: Clinical recovery from COVID-19 symptoms was defined as: temperature \< or equal to 37.7 degrees Celsius (surface by infra-red or oral), respiratory rate \< or equal to 24/minute on room air, shortness of breath is absent on a patient-report scale, and cough is mild or absent on a patient-reported scale.; timeFrame: Day 14 [± 1 day]

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history